RxDoctor Payments Data

Andrew Braun, MD

Pulmonary Disease · Madison, WINPI 1235338062

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Vertex accounts for 100.0% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2019 at $26,760 and has fallen 85.7% since, to $3,825 in 2023. Among pulmonary disease clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$32,507in general payments, 2019–2025

Across 27 payments — averaging $1203.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$32K
  • Roche Diabetes Care, Inc.$11
$1,538,584in research payments, 2019–2025

Across 57 payments — averaging $26,993 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$1.5M
  • Boehringer Ingelheim International GmbH$5K

What the payments were for

  • Consulting fees$18,53157%
  • Travel & lodging$13,58542%
  • Food & beverage$3801%
  • Education$110%

General payments by program year

19
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Vertex26$32,496
Roche Diabetes Care, Inc.1$11

How this compares

$32,507 in reported general payments places this provider in the 90th percentile of 247 pulmonary disease providers in Wisconsin.

See all pulmonary disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$45,478
Medicare patients
184
Services billed
619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrikaftaElexacaftor/Tezacaftor/Ivacaft116$3,013,989
KalydecoIvacaftor12$285,996
CreonLipase/Protease/Amylase21$138,408
ZenpepLipase/Protease/Amylase14$87,857
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,788
Albuterol Sulfate HfaAlbuterol Sulfate43$2,652
Ventolin HfaAlbuterol Sulfate14$1,664
Ursodiol18$1,310
Azithromycin38$547
Fluticasone Propionate26$281
Pregabalin14$229
Spironolactone16$221
Trazodone Hcl22$121
Prednisone26$90
Furosemide13$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
VertexTrikafta, Kalydeco$32,496$3,299,985128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 247 pulmonary disease providers in Wisconsin.

Other pulmonary disease in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →